% 0期刊文章%卡米拉Piccinin %一个Luiza Piovesana %玛丽亚克里斯蒂娜•桑托斯%一个瑞秋吉马良斯% Paula代理% Lidiane Campos %奥古斯托。Amato-Filho % Marcondes语言,小%一个Iscia Lopes-Cendes %费尔南多Cendes % Anelyssa D 'Abreu % T灰质萎缩主要Craniocervical肌张力障碍(P02.085) % D J神经病学2013% % P P02.085-P02.085 % V 80% N % X 7补充目的:执行灰质(GM)评价患者的整个大脑的初级Craniocervical肌张力障碍(PCCD)。首页背景:PCCD是最常见的成人肌张力障碍。临床表现为睑痉挛,oromandibular舌、喉、颈肌张力障碍隔离或组合。先验分布形态测量学(VBM)研究通用描述病人些微变化PCCD,然而没有一个清晰的模式。设计/方法:我们分析了30 PCCD患者(59.47±12.06岁)与105年相比健康对照组(43.44±16.62年)。所有患者正常TOR1A基因第5外显子测序。疾病持续时间是10±6.91年,肉毒毒素治疗持续时间5.47±5.14年,Marsden-Fahn量表得分为5.44±2.68。t1影像进行3特斯拉扫描仪。我们使用SPM8 / Dartel软件中实现Matlab R2011b VBM的分析。使用协方差的同质性测试导致5患者和1控制的排斥。统计分析,我们两个示例测试执行(family-wise纠错与p < 0.05)和程度阈值20像素点。RESULTS: In PCCD, VBM demonstrated significant atrophy (clusters ≥ 100 voxels) of GM at the left hemisphere: temporal pole of the superior temporal gyrus, middle temporal gyrus; middle occipital gyrus; inferior frontal gyrus (orbital part and triangular part), superior medial frontal gyrus and dorsolateral prefrontal cortex. In the right hemisphere the clusters were manly in the frontal lobe, however too small to be reported. There was no significant GM excess or significant correlation between clinical and imaging findings.CONCLUSIONS: We were able to demonstrate significant brain atrophy in multiple cortical areas in patients with PCCD. Interestingly, there was a clear lateralization towards the left in our sample and a predominant frontal lobe involvement. Our results are somewhat different than previously reported, however our sample is larger, with well defined and much larger control group.Supported by: FAPESP.Disclosure: Dr. Piccinin has nothing to disclose. Dr. Piovesana has nothing to disclose. Dr. Santos has nothing to disclose. Dr. Guimaraes has nothing to disclose. Dr. Azevedo has nothing to disclose. Dr. Campos has nothing to disclose. Dr. Amato-Filho has nothing to disclose. Dr. Franca, Jr. has nothing to disclose. Dr. Lopes-Cendes has nothing to disclose. Dr. Cendes has nothing to disclose. Dr. D'Abreu has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals, Inc., EMS, Roche, and Novartis.Tuesday, March 19 2013, 7:30 am-12:00 pm %U